For V600E mutations in NSCLC, following the successful application of double BRAF/MEK inhibition in melanoma, two phase II trials with dabrafenib and trametinib were conducted on pretreated and treatment-naive patients with metastatic lung adenocarcinoma. Here, MAP2K7 is linked to melanoma.